As EMT, invasive ability, and cancer stemness are usually associated with dedifferentiation and are well-known phenotypes contributing to a poor therapeutic response to contemporary treatments, we attempted to determine the role of CD200 in the evolutional induction of chemoresistance in human and mouse HNSCC models. The gene discussed is CD200; the disease is head and neck squamous cell carcinoma.